Injectable alcoholism drug developed

Jun 13, 2006

A U.S. biotech firm has reportedly developed a monthly injectable alcoholism treatment as a substitute for a daily pill.

The drug -- being marketed by Cephalon Inc., in Frazer, Pa. -- was developed by Alkermes Inc. of Cambridge, Mass., as an extended-release injection form of naltrexone.

The new drug, Vivitrol, works by blocking neurotransmitters believed to be associated with alcohol dependence, diminishing the craving for alcohol, the Philadelphia Inquirer reported Tuesday.

Vivitrol has been approved by the U.S. Food and Drug Administration for use by adults able to abstain from drinking alcohol in an outpatient setting, and who are not actively drinking when they begin treatment.

The monthly intramuscular shot will cost $695, with Alkermes and Cephalon sharing profits from Vivitrol sales, as well as developing future commercial uses, possibly to treat other addictions.

Researchers told the Inquirer Vivitrol will be administered only by healthcare personnel in offices, hospitals, and clinics, and the treatment will include counseling.

Copyright 2006 by United Press International

Explore further: Liberia works to contain Ebola, find source of new cases

Related Stories

Longer-lasting options to treat drug addiction

Oct 18, 2010

(AP) -- New treatments for addiction to heroin or narcotic painkillers promise longer-lasting relief that may remove some day-to-day uncertainty of care: A once-a-month shot is now approved and a six-month implant is in ...

Recommended for you

Noise from fireworks threatens young ears

14 hours ago

(HealthDay)—The Fourth of July weekend is a time for celebrations and beautiful fireworks displays. But, parents do need to take steps to protect their children's ears from loud fireworks, a hearing expert ...

Many new teen drivers 'crash' in simulated driving task

14 hours ago

(HealthDay)—Around four in 10 newly licensed teen drivers "crashed" in a simulated driving test, suggesting that many adolescents lack the skills they need to stay safe on the road, according to a new study.

New test could predict arthritis drug failure in patients

15 hours ago

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.